Alex Chehrazi-Raffle, MD

On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis & checkpoint inhibition. If you are at the @AACR @theNCI @EORTC #Targets25, come visit our poster in the session starting at noon today - if not, read below ... (1/8)

First glimpses into saruparib in PETRANHA by @AzadOncology Surprised by the comparable rates of anemia. Has encouraging initial activity but hard to differentiate from ARPI alone given study design. Await P3 data

Hot off the presses 📰 our @JCOPO_ASCO study shows ctDNA can detect MRD in GCTs, outperforming STMs. Huge multi-center #TeamScience effort—proud of this crew! 💪 @rebeccahassoun @ReubenBenDavid1 @nabiladra @DrJohnSfakianos @TDorffOnc @NateraGenetics 👉ascopubs.org/doi/full/10.12…

A must-read editorial in @EUplatinum by @NazliDizman @EbrahimiHedyeh and @arafflemd on the current state of non-clear cell RCC! @OncoAlert @DrChoueiri @DrYukselUrun @MikeSerzanMD #KidneyCancer #oncology #MedX @montypal 👉doi.org/10.1016/j.euru…

Terrific job @brian_rini & @tompowles1. Particularly enjoyed the discussion around #neoadjuvant design. Folks, if you are planning a neoadjuvant study in #kidneycancer please consider getting in touch with #AxelBex & his colleague @grantissimus. They have put lots of thought into study methodology & endpoints in this setting. At #KCRS25, one of my favorite moments was sitting down with them @WesleyYipMD to hone endpoints in a study Wes is designing with his @ASCO CDA.

Incredibly honored to be featured on the cover of the June issue of @CD_AACR. This work supported by @CRUKresearch as a part of the MUTOGRAPHS Grand Challenge Awards and the @theNCI F32 fellowship encompasses efforts decades in the making spearheaded by my mentor Prof. Allan Balmain. Our finding underscore a critical issue that is deeply under-appreciated concept in the cancer prevention and control policy and research, which is the importance of cancer promotion as a tumorigenic mechanism. Specifically, initiated tissue-resident cells bearing driver mutations can remain latent for a long period of time awaiting a signal to divide and become “cancer”. Thus, there is a critical need to better understand the mechanisms of promotion (which include some that we investigated like obesity and inflammation) but also many others that we do not yet understand or appreciate. Excited for the next phase of this work being funded by the @CRUKresearch PROMINENT and @NIH_CommonFund DP5 awards to better understand the mechanism of cancer promotion.

@OncLive @cityofhope @ASCO Thanks @OncLive for the opportunity to chat about our subgroup analysis for TiNivo-2! @AVEOPharma @DrChoueiri @AlbigesL @PBarataMD @motzermd

Huge thank you to @arafflemd of @cityofhope for expanding on key data from an efficacy analysis of tivozanib with/without nivolumab in select pretreated patients with ccRCC from the phase 3 TiNivo-2 study! Check back at onclive.com to learn more. @ASCO #ASCO25 #kcsm

1/ Huge thanks to all collaborators, but especially to @arafflemd , great friend and mentor, for the opportunity to contribute to this multicenter study on HDCT in refractory/recurrent #GCT!

🚨Check out our multicenter study that compared the most commonly used high-dose chemo regimens for refractory #GCT. HUGE thanks to our collaborators at @UCSFCancer @UCDavisHealth @UCLAHealthJCCC, and @mzugman @montypal @TDorffOnc @matthew_mei for their leadership & support! 🙏🏼

Had a chance to celebrate @arafflemd's new paper in @ESMO_Open (co-first auth: @mzugman) over lunch today at @SWOG! This multicenter collaboration exploring HDCT regimens (CE/TICE) required years of effort in which he pooled data across @cityofhope, @UCSFCancer, @uscnorris & @UCD_Cancer. He was asked by @cityofhope leadership to build our program in #testicularcancer & has done a simply phenomenal job in this regard.

🎖️Trainees in oncology and across all fields of medicine! Do not miss this manuscript on how to effectively respond to reviewer comments! Thanks @VickersBiostats @redunndant @cgratzke @MRoupret @Albert0Briganti et al. @EUplatinum @EurUrolFocus @EurUrolOncol 🙏 @OncoAlert @ASCOTECAG @IMG_Oncologists @HemOncFellows @HemOncWomenDocs #MedEdCoP #Meded #OncTwitter @YaleIMed @ASCO @ASH_hematology

Best talk I have been to all year was right here at @cityofhope at our GU retreat (organized by @arafflemd). @yunroseli @COH_RadOnc just delivered a tour de force highlighting her work in #prostatecancer w @TDorffOnc et al focused on fasting interventions & other metabolic strategies. Well executed @NIH funded studies w rich correlatives; recently funded effort looking at #GLP1 alongside @JuneWRhee thanks for a massive @American_Heart grant. Keep up the amazing work, Rose! Proud of you.

🧵 1/7 Newly published @JCO_ASCO #OncologyAdvances! Our study explores how insurance status affects survival outcomes for patients with metastatic renal cell carcinoma (mRCC) receiving first-line systemic therapy. Read here: doi.org/10.1200/OA.24.…

Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq

I am so proud! @KahlaSalgia has one of the kindest hearts I have ever met among any of my students. It was an honor to work with her & look forward to seeing her continue to rise with my dear friends at @HarborUCLA! @arafflemd @TDorffOnc @DrMvandenBrink @AbhiTrip87 @AlexisLevee @DrAryaAmini @charlesbnguyen

So long #GU25! See you next year ✌🏼

🚀 First-Time at @ASCO #GU25? Here’s What You Need to Know! 🎯 📅 Plan ahead! This is more intimate than ASCO, so take advantage of smaller sessions to connect with experts 💬 Engage with presenters! 📲 Don’t just attend, participate! Share insights on #GU25, join discussions, and connect beyond the meeting 🔎 Poster sessions = hidden gems! Great discussions and new collaborations start here

We are getting awfully close to a full house for #SoCalGU25! Come join us at the @BalboaBayClub on Friday, Feb 28, for full day of #clinicaltrial discussions on #GU cancers. We look forward to hosting speakers from @UCIrvine, @UCLAHealth, @USC_Urology, @cityofhopeoc, @LLU_Urology, @UCSDCancer & more! Fellows - we are looking for posters! Special guest @AndreaNecchi doing our keynote & terrific panelists including @TDorffOnc @jgong15 @siadaneshmand @WesleyYipMD @arafflemd @AbhiTrip87 @KidneyCancerDoc @DrTylerStewart & so many more! Register here: #group-tabs-node-course-default6" target="_blank" rel="nofollow noopener">cme.cityofhope.org/content/2nd-an…

Southern California fellows, residents, medical students, and early-career researchers in #GU cancers: Showcase your latest research in prostate, bladder, kidney, and other #GUcancers at the 2nd Annual Southern California Genitourinary Cancer Research Forum @SoCalGUResearch on Feb 28! Submit your poster by Feb 6: #group-tabs-node-course-default1" target="_blank" rel="nofollow noopener">cme.cityofhope.org/content/2nd-an…

@ConquerCancerFd @ASCO Congrats to all of the @ConquerCancerFd merit award recipients, especially our very own @EbrahimiHedyeh! @CityofHope_GU @COHMedOnc @AbhiTrip87 @charlesbnguyen @TDorffOnc @montypal

We are pleased to announce the recipients of 2025 Genitourinary Cancers Symposium Merit Awards to recognize first authors on top-ranking abstracts selected for presentation at the @ASCO Genitourinary Cancers Symposium, 2/13–15, in San Francisco. Congrats! brnw.ch/21wQptf